0.5 mg of semaglutide Wegovy® / 0.5 mL Injection 4 Poviztra® Semaglutide 0.5 Injection Pen

Image Credit: zimmytws / Shutterstock A recent review article published in the Journal of Clinical Investigation summarized the adverse effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual incretin receptor agonists such as tirzepatide

Because if you're doing strength training over 40, especially, and you feel like you're working hard, you're following a program, you're showing up three, four, five days a week to the gym, and the muscle isn't developing the way that you expected, or you're not getting stronger, or you're hitting a wall, this episode is for you

Armed with this knowledge, you move from frustration to empowerment, confident that your treatment plan reflects your unique physiology rather than a one-size-fits-all template

2021 FDA Mounjaro Prescribing Information 2025 FDA Rybelsus Prescribing Information 2025 Tirzepatide StatPearls NCBI Bookshelf Semaglutide StatPearls NCBI Bookshelf PIONEER 1 Trial Diabetes Care 2019 Lilly SURPASS-2 Press Release FDA Approves Oral Semaglutide for CV Risk Reduction AJMC Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice

Healthcare providers alter the dose of medicine based on how well it works and how the patient handles it

Thus, tirzepatide appears to outperform semaglutide at doses that comparably engage the GLP-1R